The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease

Matteoni, 1999, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology, 116, 1413, 10.1016/S0016-5085(99)70506-8

Teli, 1995, The natural history of nonalcoholic fatty liver: a follow-up study, Hepatology, 22, 1714, 10.1002/hep.1840220616

Lee, 1989, Nonalcoholic steatohepatitis: a study of 49 patients, Hum Pathol, 20, 594, 10.1016/0046-8177(89)90249-9

Chitturi, 2002, NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome, Hepatology, 35, 373, 10.1053/jhep.2002.30692

Chalasani, 2003, Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 98, 1849, 10.1111/j.1572-0241.2003.07619.x

Musso, 2003, Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis, Hepatology, 37, 909, 10.1053/jhep.2003.50132

Cassader, 2001, Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients, Lipids, 36, 1117, 10.1007/s11745-001-0822-5

Willner, 2001, Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease, Am J Gastroenterol, 96, 2957, 10.1111/j.1572-0241.2001.04667.x

Tiikkainen, 2002, Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes, Obes Res, 10, 859, 10.1038/oby.2002.118

Sanyal, 2001, Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities, Gastroenterology, 120, 1183, 10.1053/gast.2001.23256

Ground, 1982, Liver pathology in aircrew, Aviat Space Environ Med, 53, 14

Hilden, 1977, Liver histology in a “normal” population–examinations of 503 consecutive fatal traffic casualties, Scand J Gastroenterol, 12, 593, 10.3109/00365527709181339

Bellentani, 2000, Prevalence of and risk factors for hepatic steatosis in Northern Italy, Ann Intern Med, 132, 112, 10.7326/0003-4819-132-2-200001180-00004

Dixon, 2001, Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese, Gastroenterology, 121, 91, 10.1053/gast.2001.25540

Garcia-Monzon, 2000, Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity, J Hepatol, 33, 716, 10.1016/S0168-8278(00)80301-3

Gupte, 2004, Non-alcoholic steatohepatitis in type 2 diabetes mellitus, J Gastroenterol Hepatol, 19, 854, 10.1111/j.1440-1746.2004.03312.x

Akbar, 2003, Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics, Diabetes Care, 26, 3351, 10.2337/diacare.26.12.3351-a

Targher, 2005, Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients, Diabetes, 54, 3541, 10.2337/diabetes.54.12.3541

Vozarova, 2002, High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes, Diabetes, 51, 1889, 10.2337/diabetes.51.6.1889

Wanless, 1990, Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors, Hepatology, 12, 1106, 10.1002/hep.1840120505

Hamaguchi, 2005, The metabolic syndrome as a predictor of nonalcoholic fatty liver disease, Ann Intern Med, 143, 722, 10.7326/0003-4819-143-10-200511150-00009

Fan, 2005, Fatty liver and the metabolic syndrome among Shanghai adults, J Gastroenterol Hepatol, 20, 1825, 10.1111/j.1440-1746.2005.04058.x

Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 40, 1387, 10.1002/hep.20466

Flegal, 2002, Prevalence and trends in obesity among US adults, 1999–2000, JAMA, 288, 1723, 10.1001/jama.288.14.1723

Moran, 1983, Steatohepatitis in obese children: a cause of chronic liver dysfunction, Am J Gastroenterol, 78, 374

Baldridge, 1995, Idiopathic steatohepatitis in childhood: a multicenter retrospective study, J Pediatr, 127, 700, 10.1016/S0022-3476(95)70156-7

Chitturi, 2001, Etiopathogenesis of nonalcoholic steatohepatitis, Semin Liver Dis, 21, 27, 10.1055/s-2001-12927

Marchesini, 2001, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844

Bugianesi, 2005, Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms, Diabetologia, 48, 634, 10.1007/s00125-005-1682-x

Seppala-Lindroos, 2002, Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men, J Clin Endocrinol Metab, 87, 3023, 10.1210/jcem.87.7.8638

Cnop, 2002, The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments, Diabetes, 51, 1005, 10.2337/diabetes.51.4.1005

Boyko, 2000, Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans, Diabetes Care, 23, 465, 10.2337/diacare.23.4.465

Miyazaki, 2002, Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus, Am J Physiol Endocrinol Metab, 283, E1135, 10.1152/ajpendo.0327.2001

Hayashi, 2003, Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans, Diabetes Care, 26, 650, 10.2337/diacare.26.3.650

Nieves, 2003, The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat, Diabetes, 52, 172, 10.2337/diabetes.52.1.172

Nicklas, 2003, Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women, Diabetes Care, 26, 1413, 10.2337/diacare.26.5.1413

Carr, 2004, Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome, Diabetes, 53, 2087, 10.2337/diabetes.53.8.2087

Kelley, 2003, Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance, Am J Physiol Endocrinol Metab, 285, E906, 10.1152/ajpendo.00117.2003

Nguyen-Duy, 2003, Visceral fat and liver fat are independent predictors of metabolic risk factors in men, Am J Physiol Endocrinol Metab, 284, E1065, 10.1152/ajpendo.00442.2002

Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621

Jensen, 1996, Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women, Metabolism, 45, 662, 10.1016/S0026-0495(96)90040-2

Basu, 2001, Systemic and regional free fatty acid metabolism in type 2 diabetes, Am J Physiol Endocrinol Metab, 280, E1000, 10.1152/ajpendo.2001.280.6.E1000

Garg, 2004, Acquired and inherited lipodystrophies, N Engl J Med, 350, 1220, 10.1056/NEJMra025261

Cnop, 2003, Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex, Diabetologia, 46, 459, 10.1007/s00125-003-1074-z

Yamauchi, 2002, Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat Med, 8, 1288, 10.1038/nm788

Hui, 2004, Beyond insulin resistance in NASH: TNF-α or adiponectin?, Hepatology, 40, 46, 10.1002/hep.20280

Bugianesi, 2005, Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity, J Clin Endocrinol Metab, 90, 3498, 10.1210/jc.2004-2240

Bajaj, 2004, Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients, Int J Obes Relat Metab Disord, 28, 783, 10.1038/sj.ijo.0802625

Xu, 2003, The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J Clin Invest, 112, 91, 10.1172/JCI200317797

Romano, 2003, Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women, J Clin Endocrinol Metab, 88, 5321, 10.1210/jc.2003-030508

Yudkin, 1999, C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?, Arterioscler Thromb Vasc Biol, 19, 972, 10.1161/01.ATV.19.4.972

Kern, 2001, Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance, Am J Physiol Endocrinol Metab, 280, E745, 10.1152/ajpendo.2001.280.5.E745

Fernandez-Real, 2001, Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women, J Clin Endocrinol Metab, 86, 1154, 10.1210/jcem.86.3.7305

Esposito, 2003, Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial, JAMA, 289, 1799, 10.1001/jama.289.14.1799

Escobar-Morreale, 2003, Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women, Diabetologia, 46, 625, 10.1007/s00125-003-1090-z

Miyazaki, 2003, Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients, Int J Obes Relat Metab Disord, 27, 88, 10.1038/sj.ijo.0802187

Crespo, 2001, Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis?, Obes Surg, 11, 254, 10.1381/096089201321336548

Kugelmas, 2003, Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E, Hepatology, 38, 413, 10.1053/jhep.2003.50316

Crespo, 2001, Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients, Hepatology, 34, 1158, 10.1053/jhep.2001.29628

Kim, 2003, Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog, Diabetes, 52, 2453, 10.2337/diabetes.52.10.2453

Samuel, 2004, Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease, J Biol Chem, 279, 32345, 10.1074/jbc.M313478200

Westerbacka, 2005, Dietary fat content modifies liver fat in overweight nondiabetic subjects, J Clin Endocrinol Metab, 90, 2804, 10.1210/jc.2004-1983

Hudgins, 1996, Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet, J Clin Invest, 97, 2081, 10.1172/JCI118645

Day, 2002, Non-alcoholic steatohepatitis: definitions and pathogenesis, J Gastroenterol Hepatol, 17, S377, 10.1046/j.1440-1746.17.s3.31.x

Luyckx, 2000, Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss, Diabetes Metab, 26, 98

Lam, 2003, Mechanisms of the free fatty acid-induced increase in hepatic glucose production, Am J Physiol Endocrinol Metab, 284, E863, 10.1152/ajpendo.00033.2003

Tamura, 2005, Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease, J Clin Invest, 115, 1139, 10.1172/JCI24930

Shimano, 1997, Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells, J Clin Invest, 99, 846, 10.1172/JCI119248

Yahagi, 2002, Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice, J Biol Chem, 277, 19353, 10.1074/jbc.M201584200

Browning, 2004, Molecular mediators of hepatic steatosis and liver injury, J Clin Invest, 114, 147, 10.1172/JCI200422422

Wolfrum, 2004, Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes, Nature, 432, 1027, 10.1038/nature03047

Biddinger, 2006, From mice to men: insights into the insulin resistance syndromes, Annu Rev Physiol, 68, 123, 10.1146/annurev.physiol.68.040104.124723

Neuschwander-Tetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone, Hepatology, 38, 1008, 10.1002/hep.1840380427

Azuma, 2002, A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis, Hepatology, 36, A406

Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4

Promrat, 2004, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis, Hepatology, 39, 188, 10.1002/hep.20012

Petersen, 2005, Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes, Diabetes, 54, 603, 10.2337/diabetes.54.3.603

Neuschwander-Tetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology, 37, 1202, 10.1053/jhep.2003.50193

Park, 1995, Effect of weight control on hepatic abnormalities in obese patients with fatty liver, J Korean Med Sci, 10, 414, 10.3346/jkms.1995.10.6.414

Ueno, 1997, Therapeutic effects of restricted diet and exercise in obese patients with fatty liver, J Hepatol, 27, 103, 10.1016/S0168-8278(97)80287-5

Suzuki, 2005, Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease, J Hepatol, 43, 1060, 10.1016/j.jhep.2005.06.008

Huang, 2005, One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study, Am J Gastroenterol, 100, 1072, 10.1111/j.1572-0241.2005.41334.x

Tiikkainen, 2003, Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content, Diabetes, 52, 701, 10.2337/diabetes.52.3.701

Tamura, 2005, Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients, J Clin Endocrinol Metab, 90, 3191, 10.1210/jc.2004-1959

Luyckx, 1998, Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty, Int J Obes Relat Metab Disord, 22, 222, 10.1038/sj.ijo.0800571

Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512

Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest, 108, 1167, 10.1172/JCI13505

Lin, 2000, Metformin reverses fatty liver disease in obese, leptin-deficient mice, Nat Med, 6, 998, 10.1038/79697

Nair, 2004, Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial, Aliment Pharmacol Ther, 20, 23, 10.1111/j.1365-2036.2004.02025.x

Marchesini, 2001, Metformin in non-alcoholic steatohepatitis, Lancet, 358, 893, 10.1016/S0140-6736(01)06042-1

Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol, 100, 1082, 10.1111/j.1572-0241.2005.41583.x

Uygun, 2004, Metformin in the treatment of patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 19, 537, 10.1111/j.1365-2036.2004.01888.x

Tiikkainen, 2004, Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes, Diabetes, 53, 2169, 10.2337/diabetes.53.8.2169

Miyazaki, 2001, Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients, Diabetologia, 44, 2210, 10.1007/s001250100031

Miyazaki, 2002, Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients, J Clin Endocrinol Metab, 87, 2784, 10.1210/jcem.87.6.8567

Virtanen, 2003, Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects, Diabetes, 52, 283, 10.2337/diabetes.52.2.283

de Souza, 2001, Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance, Diabetes, 50, 1863, 10.2337/diabetes.50.8.1863

Mayerson, 2002, The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes, Diabetes, 51, 797, 10.2337/diabetes.51.3.797

Gomez-Perez, 2002, Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution, Metabolism, 51, 44, 10.1053/meta.2002.29024

Yu, 2002, The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects, Diabetes, 51, 2968, 10.2337/diabetes.51.10.2968

Phillips, 2003, Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy, Diabetes, 52, 667, 10.2337/diabetes.52.3.667

Yang, 2002, Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients, Diabetes Care, 25, 376, 10.2337/diacare.25.2.376

Pajvani, 2004, Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity, J Biol Chem, 279, 12152, 10.1074/jbc.M311113200

Singh Ahuja, 2001, Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents, Mol Pharmacol, 59, 765, 10.1124/mol.59.4.765

Marx, 2002, PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis, Circ Res, 90, 703, 10.1161/01.RES.0000014225.20727.8F

Marx, 2003, Antidiabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease, Arterioscler Thromb Vasc Biol, 23, 283, 10.1161/01.ATV.0000054195.35121.5E

Raji, 2003, Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients, Diabetes Care, 26, 172, 10.2337/diacare.26.1.172

Kernan, 2003, Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke, Stroke, 34, 1431, 10.1161/01.STR.0000071108.00234.0E

Wang, 2004, Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome, Am J Cardiol, 93, 362, 10.1016/j.amjcard.2003.10.022

Acosta, 2001, The use of pioglitazone in nonalcoholic steatohepatitis, Gastroenterology, 120, A546, 10.1016/S0016-5085(01)82715-3

Hatzitolios, 2004, Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia, Indian J Gastroenterol, 23, 131

Rallidis, 2004, Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study, Atherosclerosis, 174, 193, 10.1016/j.atherosclerosis.2004.01.008

Ogawa, 2003, Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate, Oncol Rep, 10, 1473

Basaranoglu, 1999, A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis, J Hepatol, 31, 384, 10.1016/S0168-8278(99)80243-8

Chang, 2006, Therapy of NAFLD: antioxidants and cytoprotective agents, J Clin Gastroenterol, 40, S51

Lindor, 2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002/hep.20092

Clark, 2005, Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease, Obes Res, 13, 1180, 10.1038/oby.2005.140

Caldwell, 2001, A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis, Am J Gastroenterol, 96, 519, 10.1111/j.1572-0241.2001.03553.x